Sign in
Enrolling by invitationPhase 3

Vitamin B3 Tablets Tested Alongside Eye Drops in Glaucoma

Tests nicotinamide, a vitamin B3 tablet, against a placebo in people with glaucoma.

Key facts

Who runs it
Singapore Eye Research Institute
Where
Singapore, SingaporeSee the 2 sites
Trial code
Registry title
Nicotinamide Supplementation in Glaucoma
Status
Enrolling by invitation
Phase
Phase 3
People taking part
520 people, planned
Started
12 Mar 2024
Expected to end
Jul 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Nicotinamide Tablet
  • Nicotinamide Placebo
Record updated
12 December 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with treated glaucoma and a measurable visual field defect. People take nicotinamide (vitamin B3) or a placebo every day for 2 years.

Age
21 years or older.
Sex
All sexes can join.
Disease stage
Treated glaucoma (POAG, PACG including normal tension glaucoma, PDG or PXFG) in one or both eyes, with a visual field defect from glaucoma and visual field loss (MD) between -2 and -18 dB.
Earlier treatment
Earlier laser treatment (selective laser trabeculoplasty) is fine if done at least 3 months before. Earlier filtering surgery is fine if done more than 6 months before. People already taking nicotinamide first stop for a 1-month washout.
Biomarker or test result
Visual acuity of 6/18 or better, and at least two earlier 24-2 visual field tests with under 16% false positives and under 21% fixation loss. Liver function tests must be normal.

Main reasons for not taking part

  • Active liver disease or end stage kidney failure
  • Taking allopurinol, carbamazepine or primidone
  • Cataracts that matter for vision, or cataract surgery in the last 3 months, or glaucoma filtration surgery in the last 6 months
  • Other conditions that can cause visual field defects, or a history of cancer in the last 5 years
  • Pregnancy, breastfeeding, women who could become pregnant, or low blood pressure

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Patients aged ³ 21 years, with definitive, treated POAG, PACG including normal tension glaucoma, PDG, PXFG in one or both eyes; Best-corrected visual acuity equal or better than 6/18; Reproducible visual field defect due to glaucoma (3 contiguous points at less than 5%) and severity of visual field loss, MD between -2 and -18 dB. This range includes people with moderate disease which optimises detection of progression; Patients must have at least two prior 24-2 VF tests which meet <16% FP and <21% fixation loss; Previous selective laser trabeculoplasty is acceptable (IOP-lowering laser treatment) if ³ 3 months prior or filtering surgery >6 months previously; Normal liver function tests; Those taking NAM already will undergo a 1-month washout period bef

Who cannot take part

  • Patients with active liver disease or end stage renal failure; Active use of allopurinol, carbamazepine, or primidone; Visually significant cataracts (example, likely to require surgery within 2 years); Cataract surgery in the last 3 months or glaucoma filtration surgery in last 6 months; Conditions that may cause non-glaucomatous visual field defect (for example, severe ptosis, cerebrovascular accident, prior panretinal photocoagulation, and other retinal or central nervous system diseases); Not able to complete study (for example, concurrent severe systemic disease); History of cancer in the last 5 years; Unable to give consent; Inability to tolerate or take nicotinamide and/or pyruvate; Women of Child Bearing Potential, pregnancy or lactation; History of Hypotension; Blood Pressure measurement of less than 90/60(

Where in Singapore

  • National University HospitalSingapore, SingaporeEnrolling by invitation
  • Singapore Eye Research InstituteSingapore, SingaporeEnrolling by invitation

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if nicotinamide (NAM, vitamin B3) supplementation can delay glaucoma progression 30% above that achieved with conventional glaucoma treatment using topical medication. The main questions it aims to answer are:

Read full original descriptionShow less

Can NAM supplementation improve the visual function of patients with glaucoma measured by visual field perimetry?

Researchers will compare NAM to a placebo (a look-alike substance that contains no drug) to see if NAM works as an adjuvant in glaucoma treatment.

Participants will:

* Take NAM or a placebo every day for 2 years * Visit the clinic once every 3-4 months for checkups and tests

The 2 groups in the trial

  • NicotinamideTreatment being tested

    1.5 grams/day (2 tablets of 750 mg each)

    Treatment: Nicotinamide Tablet

  • PlaceboPlacebo, for comparison

    2 tablets

    Treatment: Nicotinamide Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Targeting Metabolic Insufficiency (TAMING) Glaucoma Study : a 2-year Multi-centre, Double-masked, Randomised, Placebo-controlled Trial of Nicotinamide (Vitamin B3) Supplementation in Glaucoma
Plain-language title
Vitamin B3 Tablets Tested Alongside Eye Drops in GlaucomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 December 2024